In addition, we wish to note that this is a descriptive/correlative paper and further studies in HFD mice (WT and NLRP3−/−) treated with enteric glial‐selective inflammasome inhibitors (unfortunately currently not available) should be required to directly test this hypothesis, thus better substantiate the relevance of the interplay among NLRP3 inflammasome, enteric gliosis, and mucosal barrier alterations in obesity. Here, NLRP3 is linked to obesity disorder.